Growing Operations Without Growing Teams: How Life Sciences Leaders Are Making It Work

 

Five Minutes That Could Reshape How You Staff Your Next Program

• Life sciences executives expect growth in 2026, but regulated talent in pharmacovigilance and medical information remains scarce and expensive.
• FSP and managed services models let you expand case-handling and MI capacity without adding permanent headcount.
• AI can automates intake, triage, and literature screening – but GxP judgment still requires skilled people.
• Only 39% of organizations are meaningfully balancing agility and stability. The ones that do, design governance upfront.
• A global staffing, workforce, and IT solutions partner can help you build the right blended model – before the next product launch or safety signal forces the issue.

Growth is back on the agenda for US life sciences leaders. According to Deloitte’s 2026 Life Sciences Outlook, executives are broadly optimistic – but the compounding talent-execution challenge in life sciences is real: AI pressure, pricing headwinds, and global workforce shifts are hitting simultaneously. Most organizations cannot simply hire their way through it.

This is especially true for pharmacovigilance and medical information. Case volumes rise with every new indication or market expansion. Headcount freezes don’t.

What follows will show you which operating models are working, where AI fits and where it doesn’t, and how to govern mixed internal-external teams without losing GxP control or budget visibility.

Why “Grow Ops, Not Teams” Is Now a Life Sciences Imperative

According to Deloitte’s 2025 Human Capital Trends research, 85% of executives say organizations need more agile ways of working – yet 75% of workers are hoping for greater stability. Only 39% of organizations are meaningfully addressing that gap.

In pharmacovigilance and medical information, that tension is most expensive. Demand spikes unpredictably: new launches, safety signals, label updates. Building a larger permanent team to absorb every peak is neither financially sustainable nor operationally efficient.

The leaders getting this right are not hiring more. They are redesigning how work gets done. Read more on AI-driven clinical and R&D platforms with compliant staffing models to see how that shift is unfolding in regulated environments.

Operating Models That Scale Pharmacovigilance and Medical Information Without More FTEs

What operating models let you handle higher PV case volumes without building a larger in-house safety team? The answer depends on how much control, flexibility, and management bandwidth you have.

Most organizations work across a spectrum:

• Internal-only teams: Highest control, lowest flexibility – workable until volumes spike.
• Staff augmentation / contingent staffing: Fast to activate and well-suited for defined skill gaps, but management-intensive without strong governance.
• PV and MI FSP models: Dedicated external teams operating under your SOPs and oversight – strong for ongoing case management, signal monitoring, or MI contact center functions.
• Managed services: Outcomes-based delivery for defined workflow segments – adverse event intake, literature screening, MI query handling.

Consider an illustrative scenario common in US life sciences: a mid-size biopharma company preparing for two simultaneous label expansions. Rather than waiting through a typical 12–18-month permanent-hire cycle for regulated roles, their COO structured a flexible contingent staffing model for regulated environments alongside a managed MI services partner. Within weeks, case-processing capacity was live, internal medical directors retained all safety decisions, and headcount stayed flat.

Deloitte’s 2026 Global Human Capital Trends report frames this as “dynamic orchestration of talent and technology” – the model that outperforms static org structures when speed matters.

For a broader framework on redefining this balance, redefining workforce management in an AI-driven economy offers a practical starting point.

AI and Automation in PV and Medical Information: Where People Still Matter Most

How should CIOs and COOs use AI in pharmacovigilance and medical information without destabilizing their workforce? Start by being specific about which tasks AI can own versus which require GxP-trained judgment.

BCG’s 2025 AI Impact research is direct: only one in four organizations are capturing real AI value. The ones that do follow the 10-20-70 rule – 10% on algorithms, 20% on data and tech, 70% on people, process, and culture. They focus on an average of 3.5 use cases, not 6, and expect 2.1x greater ROI.

In PV and MI, AI adds measurable value in:

• Case intake and triage: Automated capture, duplicate detection, MedDRA coding assistance
• Literature surveillance: Screening and flagging, reducing manual review time
• MI contact center: Intent classification and response templating

It does not replace signal evaluation, causality assessment, or complex MI queries requiring clinical interpretation.

BCG’s AI at Work 2025 findings show frontline AI adoption has stalled at 51%, despite more than three-quarters of leaders using GenAI weekly. Only one-third of employees say they have been properly trained. That gap reflects insufficient workflow redesign — not lack of tools. Organizations using technology staffing services for AI and cloud platforms are closing it by bringing in AI-literate specialists to run implementation alongside internal teams.

Governance, GxP, and Total Cost of Ownership in Mixed Internal-External Models

How do life sciences executives ensure GxP and regulatory compliance when most safety activities are handled by external partners? The key is to implement a governance framework from the beginning, rather than adding it after the first audit reveals issues.

Effective governance for outsourced pharmacovigilance and medical information defines:

• Clear RACI across internal leads, vendor team leads, and quality oversight
• Escalation paths for safety signals and urgent MI responses
• Quality KPIs: case turnaround, error rates, audit-readiness scores
• Shared audit trail access and SOP alignment

Total cost of ownership matters as much as headline rates. Management overhead, rework cycles, compliance remediation, and vendor-switching costs rarely appear in the original business case. Centralized contingent workforce governance and visibility reduces that hidden cost significantly when you are running multiple external partners across a safety program.

What CIOs, CHROs, COOs, and CFOs Should Do Next

Three actions that generate momentum ahead of the next launch cycle or a safety event when urgency is needed:

1. Segment your PV and MI workflows into must-stay-internal, candidate for FSP or managed services, and candidate for AI-assisted automation.
2. Build joint capacity plans with internal teams and project-based staffing and managed teams partners – not reactive requisitions triggered by backlog.
3. Define your metrics now: time-to-capacity, cost per case, error rate, audit outcomes, and workforce stability. You cannot govern what you cannot measure.

Ready to Design a Model That Scales With You?

If you are planning for a product launch, a safety system migration, or a medical information scale-up and want a clear view of what operating model fits your situation, talk to our team – we will help you map your current state and identify the fastest path to scalable, compliant capacity.

FAQ: Executives’ Common Questions on Growing Operations Without Growing Teams

Which operating models enable us to handle higher PV case volumes without building a larger in-house safety team?
FSP and managed services models are the most effective for sustained volume growth. FSPs operate under your SOPs and oversight; managed services deliver outcomes for defined workflow segments such as case intake or literature screening. Both activate faster than a permanent hire cycle and scale down when volumes normalize.

How can CFOs compare the true cost of adding FTEs versus scaling through external PV and medical information partners?
Model total cost of ownership, not just salary. Permanent hires in regulated roles carry recruiting time, benefits, onboarding, training, and offboarding costs. Pharmacovigilance managed services USA partners absorb those costs, allowing the budget to flex with program demand.

How do PV FSP models compare with traditional outsourcing in terms of control, quality, and ROI?
FSP models give sponsors more process control – your SOPs, your systems, your oversight. Traditional outsourcing transfers more operational accountability to the vendor. For life sciences organizations that need GxP compliance visibility, FSP typically offers a better risk-adjusted return.

Which safety and medical information workflows are best suited for AI-assisted automation versus human-only work?
AI adds measurable value in structured, repeatable tasks: intake, triage, coding, literature screening, and contact center routing. Human judgment remains essential for signal evaluation, causality assessment, and complex clinical queries. The right AI strategy automates the volume, not the decisions.